Epidemiology

Global Urinary Tract Infections Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:40am

b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Urinary Tract Infections patients, history of the disease at the population level (Urinary Tract Infections prevalence, Urinary Tract Infections incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nUrinary Tract Infections patient flow: Urinary Tract Infections prevalence, diagnosed, and drug-treated patients\nDemographics: Urinary Tract Infections patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Urinary Tract Infections market sizing, assessing market potential, and developing drug forecast models\nIdentify Urinary Tract Infections patients segments through age groups, gender, and disease sub-types\nEvaluate Urinary Tract Infections market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005206/en/\n'

Global Glioma Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:17am

b'The "Global Glioma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Glioma Epidemiology and Patient Flow Analysis - 2021, provides Glioma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Glioma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Glioma Epidemiology and Patient Flow Analysis - 2021, provides Glioma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Glioma patients, history of the disease at the population level (Glioma prevalence, Glioma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Glioma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Glioma market sizing, assessing market potential, and developing drug forecast models\nIdentify Glioma patients segments through age groups, gender, and disease sub-types\n'

Global Neuroblastoma Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:08am

b'The "Global Neuroblastoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Neuroblastoma Epidemiology and Patient Flow Analysis - 2021, provides Neuroblastoma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Neuroblastoma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Neuroblastoma Epidemiology and Patient Flow Analysis - 2021, provides Neuroblastoma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Neuroblastoma patients, history of the disease at the population level (Neuroblastoma prevalence, Neuroblastoma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Neuroblastoma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Neuroblastoma market sizing, assessing market potential, and developing drug forecast models\nIdentify Neuroblastoma patients segments through age groups, gender, and disease sub-types\n'

Global Gout Markets, Epidemiology and Patient Flow Report 2020-2035: Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:05am

b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Gout patients, history of the disease at the population level (Gout prevalence, Gout incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Gout patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Gout market sizing, assessing market potential, and developing drug forecast models\nIdentify Gout patients segments through age groups, gender, and disease sub-types\n'

Alveo Technologies Appoints Veteran Biotech and Diagnostics Leader to Board of Directors

Thursday, May 13, 2021 - 3:11pm

In this role, Gunn led the sequencing business from an early initial concept to a high-functioning organization of 900 team members across three continents.

Key Points: 
  • In this role, Gunn led the sequencing business from an early initial concept to a high-functioning organization of 900 team members across three continents.
  • "I\'m honored to accept nomination to Alveo\'s board, where I look forward to offering my perspective on developing the infrastructure that will enable a successful go-to-market campaign.
  • "\n"As Alveo creates what we hope will be the industry-leading platform for rapid, accessible and affordable infectious disease testing, we are fortunate to welcome a biotech and diagnostics leader of Neil\'s caliber to our board of directors," said Ron Chiarello, Ph.D., Founder, CEO and Chairman of the Board of Alveo.
  • Affordable access to real-time results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks.

Global Surgical Site Infection (SSI) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Thursday, May 13, 2021 - 2:03pm

b'The "Surgical Site Infection (SSI) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis \'Surgical site infection (SSI)-Epidemiology Forecast - 2030\' report delivers an in-depth understanding of the Surgical site infection (SSI), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.\nThe Surgical site infection (SSI) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.

Key Points: 
  • b'The "Surgical Site Infection (SSI) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis \'Surgical site infection (SSI)-Epidemiology Forecast - 2030\' report delivers an in-depth understanding of the Surgical site infection (SSI), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.\nThe Surgical site infection (SSI) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
  • This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.\nThe disease epidemiology covered in the report provides historical as well as forecasted surgical site infection (SSI) epidemiology segmented as the Total Surgical Procedures, Number of Surgical Procedures by Type, Total Incident cases of Surgical Site Infections (SSI) and Incidence of Surgical Site Infections (SSI) by Type.\nThe report includes the Incident scenario of Surgical site infection (SSI) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.\nThe epidemiology segment also provides the Surgical site infection (SSI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\nThe total Incident population of Surgical site infection (SSI) Associated in 7MM countries was estimated to be 1,275,912 cases in 2020 and expected to decline at a CAGR of ?5.11% for the study period, i.e., 2018-2030.\nAmong the EU5 countries, UK had the highest Incident population of surgical site infection (SSI).
  • This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.\nWhat are the key findings of surgical site infection (SSI) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?\nWhat are the disease risk, burden, and unmet needs of surgical site infection (SSI)?\nQuantify patient populations in the global Surgical site infection (SSI) market to improve product design, pricing, and launch plans\nThe Surgical site infection (SSI) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.

2021 Global Alzheimer's Disease Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Thursday, May 13, 2021 - 11:33am

b'The "Global Alzheimer\'s Disease Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report, Global Alzheimer\'s Disease Epidemiology and Patient Flow Analysis - 2021, provides Alzheimer\'s Disease epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Alzheimer\'s Disease Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report, Global Alzheimer\'s Disease Epidemiology and Patient Flow Analysis - 2021, provides Alzheimer\'s Disease epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Alzheimer\'s Disease patients, history of the disease at the population level (Alzheimer\'s Disease prevalence, Alzheimer\'s Disease incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Alzheimer\'s Disease patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Alzheimer\'s Disease market sizing, assessing market potential, and developing drug forecast models\nIdentify Alzheimer\'s Disease patients segments through age groups, gender, and disease sub-types\nEvaluate Alzheimer\'s Disease market opportunities, identify target patient population\n'

IMM124E – May offer a New modality for Inhibition of SARS-CoV-2

Thursday, May 13, 2021 - 11:00am

Different studies have demonstrated the existence of cross-reactive immunity through shared sites/epitopes between the bovine and human viruses.

Key Points: 
  • Different studies have demonstrated the existence of cross-reactive immunity through shared sites/epitopes between the bovine and human viruses.
  • Thus, it appears that the immunological homology in highly conserved structures between the two viruses may be the cause of the reported inhibition.
  • Dr Peres will be responsible for leading and managing the company\xe2\x80\x99s clinical development programs with a preliminary focus on COVID-19.
  • Dr Peres was previously engaged by Immuron to manage the company sponsored NASH phase II clinical trial.\nThis release has been authorised by the directors of Immuron Limited.\n'

Vyv Announces Groundbreaking Inactivation And Killing Of Viruses With Its UV-free Antimicrobial Light Technology

Wednesday, May 12, 2021 - 1:00pm

b'LATHAM, N.Y., May 12, 2021 /PRNewswire/ --Vyv, a female founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.

Key Points: 
  • b'LATHAM, N.Y., May 12, 2021 /PRNewswire/ --Vyv, a female founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.
  • The recent findings of enhanced efficacy against viruses greatly expands the antimicrobial impact delivered to spaces currently protected with Vyv technology, as well as in new spaces," said Vyv CEO and co-founder Colleen Costello.
  • Unlike UV-C light, Vyv meets international standards for continual and unlimited use around people in homes, public places and across industries.
  • Use of Vyv antimicrobial light is not intended to replace manual cleaning.\n'

Global Migraine Epidemiology Forecast to 2030 - Key Growth Opportunities - ResearchAndMarkets.com

Wednesday, May 12, 2021 - 11:44am

b'The "Migraine - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine.

Key Points: 
  • b'The "Migraine - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine.
  • The opinion helps understand the total patient population and current treatment pattern.
  • This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.\nWhat will be the growth opportunities in the 7MM concerning the patient population about migraine?\nWhat are the key findings of Migraine epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2030)?\nWhat are the disease risk, burden, and unmet needs of migraine?\nWhat are the currently available treatments for migraine?\nQuantify patient populations in the global Migraine market to improve product design, pricing, and launch plans\nThe Migraine Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies.
  • Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources\n'